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The present studyaddressed themodulatory role of CC chemokine receptor 4 (CCR4) in Toll-
like receptor (TLR) 9-mediated innate immunity and explored the underlying molecular
mechanisms. Our results demonstrated that CCR4-deficient mice were resistant to both
septic peritonitis induced by cecal ligation and puncture (CLP) and CpG DNA/D-
galactosamine-induced shock. In bone marrow-derived macrophages (BMMU) from CLP-
treated CCR4-deficient mice, TLR9-mediated pathways of MAPK/AP-1, PI3K/Akt, and IjB
kinase (IKK)/NF-jBwere impaired compared towild-type (WT) cells.While TLR9 expression
was not altered, the intensity of internalized CpG DNA was increased in CCR4-deficient
macrophages when compared to WT macrophages. Pharmacological inhibitor studies
revealed that impaired activation of JNK, PI3K/Akt, and/or IKK/NF-jB could be responsible
for decreased proinflammatory cytokine expression in CCR4-deficient macrophages.
Interestingly, the CCR4-deficient BMMU exhibited an alternatively activated (M2)
phenotype and the impaired TLR9-mediated signal transduction responses in CCR4-
deficient cells were similar to the signaling responses observed inWT BMMU skewed to an
alternatively activated phenotype. These results indicate that macrophages deficient in
CCR4 impart a regulatory influence on TLR9-mediated innate immunity.
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Introduction
The innate immune system is the first line of defense for protecting
the host against invading microbial pathogens and involves a
number of host defense systems, including chemokine-directed
movement of inflammatory cells and pathogen detection via
pattern recognition receptors (PRR) [1–3]. Chemokines bind to
chemokine receptors, which are cell-surface G protein-coupled
receptors (GPCR), leading to subsequent inflammatory signaling
events involving various second messengers [4, 5]. Chemokine
receptor ligation ultimately leads to cell signaling events via PI3K,
MAPK/AP-1, and the NF-jB pathways [5–7]. Toll-like receptors
(TLR) are major PRR that have evolved to recognize pathogen-
associated molecular patterns (PAMP), which are conserved
molecules of invading pathogens. After ligand binding, the
majority of TLR recruit the adaptor protein MyD88, which
together forms a complex with IL-1 receptor-associated kinase
(IRAK) 4, IRAK1, and TNF receptor-associated factor 6 (TRAF6).
TRAF6 subsequently activates TGF-b-activated kinase 1 (TAK1),
which in turn activates MAPK/AP-1 and the IjB kinase (IKK)/
NF-jB signaling pathways, resulting in a rapid innate immune
response [1, 3]. Clearly, these two disparate groups of receptors
evoke similar signaling pathways, but the manner in which
chemokine receptors and TLR interact during innate immunity is
poorly understood.
CC chemokine receptor 4 (CCR4), a specific receptor for
CCL17 and CCL22, is generally recognized as a receptor expressed
on Th2 cells [8–10]. However, increasing evidence has confirmed
that CCR4 is expressed not only in Th2 cells but also in
CD4+CD25+ T regulatory cells [11, 12], NK cells [13], platelets
[14], DC [15], and macrophages [16, 17]. Additionally, CCR4
appears to be a key receptor in the innate immune response as
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CCR4–/– mice are more resistant to LPS-induced sepsis [16, 18].
However, the cellular signal transduction events accounting for
the protection and resistance in CCR4–/– mice have not been fully
elucidated.
TLR9 selectively binds unmethylated CpG DNA motifs, which
are common in the prokaryote genomes of most bacteria and DNA
viruses and possess strong immunostimulatory activities [1,
19–21]. Unlike most PRR, TLR9 is mainly located in the endosome
and cells must internalize CpG DNA into acidified endosomes in
order to bind/activate TLR9. Further, IFN-c-inducible protein 10
(IP-10 or CXCL10), a type 1 (Th1) chemokine, can also be
produced by CpG DNA stimulation [22, 23]. TLR9 activation via
CpG DNA ligand has been reported to play a pivotal role in the
pathophysiology of sepsis [24] and severely injured patients with
sepsis showed higher surface expression of TLR9 in B lymphocytes
compared to healthy controls [25]. In a corollary animal model of
experimental sepsis, elevated TLR9 expression in NKT cells and
macrophages was associated with organ injury [26].
Macrophages can be differentially activated to express a
specific protein phenotype with specialized functionalities in
response to exposure to microenvironmental signals such as
cytokines and microbial products. In the same fashion of the Th1/
Th2 paradigm, the polarized macrophages can be divided into at
least two groups, classically activated (or M1) and alternatively
activated (or M2) macrophages [27–29]. Classical activation (M1)
is mediated by the priming stimulus IFN-c either alone or in
concert with microbial trigger such as LPS. One of the hallmarks of
M1 activation is the generation of NO by iNOS [27]. On the other
hand, alternative activation (M2) is generally mediated by Th2
cytokines such as IL-4 and/or IL-13. Found in inflammatory zone-
1 (FIZZ1), Arginase-1, andMannose receptor are major markers of
alternative macrophage activation. M2 macrophages have been
shown to be correlated with resolution of excessive inflammation,
wound repair, and promoting tumor progression, while M1
macrophages appeared to be significantly involved in pathogen
defense [27]. We previously reported that peritoneal macrophages
from CCR4–/– mice possess features of anM2 phenotype. However,
intracellular activation circuits that M2macrophages rely upon for
signal transduction are not well understood.
In the present study, we explored the modulation of TLR9-
mediated innate immunity in CCR4–/– mice and investigated the
molecular mechanisms of this regulation. Our studies demonstrate
that CpG DNA activation of bone marrow-derived macrophages
(BMMU) recovered from CCR4–/– septic mice possess a drama-
tically altered signal transduction profile, as compared to their WT
counterpart. Further, the signal-transduction pathways that are
altered in the CpG DNA-challenged BMMU recovered from the
CCR4–/– mice are nearly identical to the signaling modifications
observed in alternatively activated BMMU derived from WT mice.
Results
CCR4–/– mice are resistant to polymicrobial sepsis and
CpG DNA-induced shock
To specifically examine the role of CCR4 on TLR9-mediated innate
immunity in vivo, we compared the susceptibility of WT and
CCR4–/– mice to cecal ligation and puncture (CLP)-induced sepsis
and to CpG/D-galactosamine (D-GalN) induced acute systemic
inflammatory response. As shown in Fig. 1A, all WT mice died
within 3 days after the initiation of polymicrobial sepsis induced
by CLP, whereas 80% of CCR4–/– mice were alive after 7 days and
were long-term survivors. In addition, all WT mice challenged
intraperitoneally with CpG DNA (20 nmol) and D-GalN (20 mg)
died within 24 h, whereas only one of seven CCR4–/– mice injected
with CpG/D-GalN died (86% survival) (Fig. 1B). We also
investigated the serum level of proinflammatory cytokines TNF-a
and IL-6 after CpG/D-GalN stimulation and found that challenged
CCR4–/– mice displayed significant suppression in serum levels of
both TNF-a and IL-6 (Fig. 1C). Our results indicate that in the
absence of CCR4 a protective effect on CLP-induced sepsis and
CpG/D-GalN-induced shock was induced in vivo and correlated
with the suppression of circulating proinflammatory cytokines.
ImpairedMAPK/AP-1 and PI3K/Akt pathways in BMMU
from CLP-treated CCR4–/– mice
Macrophages have been shown to play a pivotal role during the
evolution of a septic response [30] and studies have identified that
severe sepsis induces a shift in these cells to an alternatively
activated (M2) macrophage that possesses a dramatically changed
Figure 1. Resistance of CCR4–/–mice to both CLP-induced sepsis andCpG
DNA-induced shock. (A) Age-matched WT (n = 13) and CCR4–/– (n = 10)
mice were subjected to CLP surgery and survival was monitored for
7 days. (B) Age-matched WT (n = 8) and CCR4–/– (n = 7) mice were
intraperitoneally injected with CpG DNA (20 nmol) and D-galactosa-
mine (D-GalN) (20 mg) and survivalwasmonitored for 5 days. (C) Serum
concentration of TNF-a and IL-6 2 h after CpG DNA/D-GalN stimulation
was measured by ELISA (n = 5 per group). *p<0.05; **p<0.005;
***p<0.0001.
Eur. J. Immunol. 2008. 38: 2290–2302 Innate immunity 2291
f 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
phenotype [16, 31]. Interestingly, CCR4–/– macrophages express
an alternatively activated phenotype [16], which formed the basis
to assess the protein expression system subsequent to TLR9
activation in BMMU from CLP-treated CCR4–/– mice. We assessed
the signal-transduction pathways that potentially could be altered
in these cells and initially focused on MAPK/AP-1 and PI3K/Akt
pathways because of their crucial role in the induction of cytokines
involved in severe acute inflammation [32, 33]. As compared to
the 0 time point, the levels of phospho (p)-JNK, p-p38 MAPK, and
p-ERK were increased in both WT and CCR4–/– BMMU at 0.5 h
after CpG DNA challenge. However, the levels of these proteins
were significantly lower in CCR4–/– BMMU compared to WT
BMMU (Fig. 2A and B). These differences were more pronounced
in BMMU from septic mice than from naivemice (data not shown).
To exclude the TLR9-independent effects of CpG DNA, BMMU
from CLP-treated WT andCCR4–/– mice were stimulated with
control non-CpG DNA for 30 min. The levels of p-JNK, p-p38
MAPK, and p-ERK were not dramatically changed in non-CpG
DNA-treated group as compared with non-stimulated group
(Fig. 2C). The expression of AP-1, a downstream transcription
Figure 2. Impaired CpG DNA-induced MAPK/AP-1 and PI3K/Akt activation in CCR4–/– BMMU. BMMU from WTor CCR4–/– mice subjected to 48 h of
CLP-induced sepsiswere stimulated by CpGDNA (1 lM) for the indicated time and thenwhole-cell lysates or nuclear extractswere prepared. (A) The
whole-cell lysates were subjected to immunoblotting using antibody for p-JNK, p-p38 MAPK, and p-ERK. Total (t)-JNK1, p38 MAPK, and t-ERK levels
are shown as loading controls, respectively. The immunoblots are representative of three independent experiments. (B) The data of (A) at 0–3 h after
CpG DNA stimulation were quantified by densitometric analysis. Data are shown asmean  SEM of three independent experiments. (C) Thewhole-
cell lysates of cells stimulated with CpG DNA or non-CpG DNA (1 lM) at 30-min time point were subjected to immunoblotting using antibody for
p-JNK, p-p38 MAPK, and p-ERK. GAPDH levels are shown as loading controls. (D) The nuclear extracts were analyzed by EMSAwith an AP-1-specific
probe. The ubiquitous nuclear protein Oct-1was used as a loading control. Datawere quantified by densitometric analysis and are shown asmean
SEM of three independent experiments. (E) The whole-cell lysates were subjected to immunoblotting using an antibody for p-Akt (pAkt Ser473). Akt
was used for loading control. (F) The data of (E) at 0–3 h after CpG stimulation were quantified by densitometric analysis. Data are shown asmean
SEM of three independent experiments. *p<0.05; **p<0.01 as compared with WT BMMU at the same time point.
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factor of JNK, p38 MAPK and ERK, was consistently lower in
CCR4–/– BMMU than in WT BMMU (Fig. 2D) (mean relative
intensities at 1 h were 1.1 and 2.4, respectively). Interestingly, it
has been previously shown that the unregulatedd expression of
p-Akt in neutrophils from septic patients can correlate with the
severity of sepsis-induced acute lung injury [32]. Here, we show
that p-Akt was up-regulated after CpG DNA challenge and was
significantly higher in BMMU from CLP-treated WT mice
compared to CLP-treated CCR4–/– mice (Fig. 2E and F). Our
results indicate that both MAPK/AP-1- and PI3K/Akt-signaling
pathways were suppressed in CpG DNA-challenged BMMU
recovered from CCR4–/– CLP-treated mice, as compared to WT
mice.
IKK/NF-jB pathway is altered in BMMU from CLP-
treated CCR4–/– mice
We next focused on IKK/NF-jB pathway, another important
pathway leading to cytokine expression during acute inflamma-
tion [32]. In this set of studies, we found that IjB-a expression
levels were not dramatically altered in either macrophage
population after CpG DNA stimulation. However, the expressions
of p-IKKa/b, p-IjB-a, and p-NF-jB (p65) were observed inWTand
CCR4–/– BMMU following CpG DNA stimulation and these levels
were significantly lower in CCR4–/– BMMU (Fig. 3A and B).
Consistent with these latter data, the NF-jB-DNA binding activities
were increased in both WTand in CCR4–/– BMMU and the binding
activity was lower in CCR4–/– BMMU from CLP-treated mice
compared to WT BMMU from CLP-treated mice (Fig. 3C) (mean
relative intensities at 1 h were 2.1 and 3.8, respectively). Together,
these results suggest that the IKK/NF-jB pathway is impaired in
macrophages from CLP-treated CCR4–/– mice.
Modulated TLR9-mediated signaling in BMMU from
CLP-treated CCR4–/– mice
Following CpG DNA recognition, TLR9 recruits the intracellular
adapter molecule MyD88 that ultimately leads to the activation of
MAPK/AP-1 and IKK/NF-jB pathways [2]. Since we showed that
TLR9-mediated MAPK/AP-1 and IKK/NF-jB pathways were
impaired in BMMU from CLP-treated CCR4–/– mice, we hypothe-
sized that signaling molecules upstream of MAPK/AP-1 and IKK/
NF-jB pathways might also be impaired in BMMU from these
mice, including TLR9 itself. To investigate this hypothesis, MyD88-
Figure 3. Impaired CpG DNA-induced activation of IKK/NF-jB pathway in CCR4–/– BMMU. BMMU fromWTor CCR4–/– mice subjected to 48 h of CLP-
induced sepsis were stimulated by CpG DNA (1 lM) for the indicated time and the whole-cell lysates or nuclear extracts were prepared. (A) The
whole-cell lysates were subjected to immunoblotting using antibody for p-IjB-a, IjB-a, p-NF-jB (p65), and p-IKKa/b. GAPDH was used as a loading
control for p-IjB-a, IjB-a, and p-NF-jB (p65), and total (t)-IKKb was the loading control for p-IKKa/b. (B) The data of (A) were quantified by
densitometric analysis. Data are shown asmean SEM of three independent experiments. (C) The nuclear extractswere analyzed by EMSAwith an
NF-jB-specific probe. Oct-1 was used as loading control. Data were quantified by densitometric analysis and are shown as mean  SEM of three
independent experiments. *p<0.05; **p<0.01 as compared with WT BMMU at the same time point.
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dependent signaling molecules in BMMU from CLP-treated WT
and CCR4–/– mice were examined after stimulation with CpG DNA
(Fig. 4). While the basal level of MyD88 in BMMU from CCR4–/–
mice was lower than that from WT mice, stimulation with CpG
DNA had no dramatic effect on subsequent MyD88 levels in either
CCR4–/– or WT BMMU (Fig. 4A). Interestingly, the expression
levels of IRAK1 and TAK1, but not of TRAF6, TRAF2 or Toll/IL-1R
domain-containing adaptor-inducing IFN-b (TRIF), were de-
creased in CLP-treated CCR4–/– BMMU after 1 h of CpG DNA
stimulation (Fig. 4A and B). We next examined the extracellular
and intracellular expression of TLR9 by flow cytometry (Fig. 4C).
The mean fluorescent intensity of TLR9 significantly increased
24 h after CpG DNA stimulation in both WT and in CCR4–/–
BMMU. However, the expression levels were not significantly
different between WT and CCR4–/– BMMU. These results suggest
that the CpG DNA-mediated MyD88-dependent signaling mole-
Figure 4. Modulated activation of TLR9-mediated signaling molecules in CCR4–/– BMMU. BMMU from WTor CCR4–/– mice subjected to 48 h of CLP-
induced sepsis were stimulated by CpG DNA (1 lM) for the indicated times. (A, B) The whole-cell lysates were subjected to immunoblotting using
antibody for MyD88, TRAF6, TRAF2, TRIF, IRAK1, and TAK1. GAPDH was used as a loading control. The immunoblots are representative of two
independent experiments. The data of (A) and (B) were quantified by densitometric analysis. (C) After stimulationwith CpGDNA for 6–24 h, the cells
(1  106) were stained with TLR9 antibody and the mean fluorescent intensity (MFI) of TLR9 was measured by flow cytometry (n = 5 per group).
Representative histograms of three independent experiments are shown. #p<0.05 as compared with untreated cells (shown as medium) in same
group. (D) After stimulation with FITC-labeled CpG DNA for 1 h, the cells (1  106) were washed and FITC bounded on cell surface was quenched by
trypan blue. Representative histograms of three independent experiments are shown.MFI of internalized CpGODNwasmeasured by flow cytometry
(n = 4 per group). #p<0.05 as comparedwith untreated cells (shown as 0 lMCpGDNA) in the same group. *p<0.05 as comparedwithWT BMMU in the
same condition.
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cules IRAK1 and TAK1 are decreased in CCR4–/– BMMU from CLP-
treated mice compared to CLP-treated WT mice and this response
is not due to altered expression of TLR9.
To determine whether the impairment of TLR9-mediated
MAPK/AP-1, IKK/NF-jB, and PI3K/Akt pathways in CCR4–/–
BMMU was due to decreased CpG DNA internalization, WT and
CCR4–/– BMMU were stimulated with FITC-labeled CpG oligonu-
cleotide (ODN), and the internalized FITC-CpG ODN was
quantified (Fig. 4D). Interestingly, the level of internalized
FITC-CpG ODN was higher in CCR4–/– BMMU than in WT
BMMU, suggesting that the defects in TLR9-mediated signaling
pathways in CCR4–/– mice were not due to inadequate amounts of
CpG DNA internalization.
Altered cytokine expression by CpG DNA in BMMU
from CLP-treated CCR4–/– mice
As TLR9-mediated signaling pathways were impaired in CCR4–/–
BMMU (Fig. 2 and 3), we hypothesized that TLR9-mediated
expression of proinflammatory cytokines should be altered in
CCR4–/– BMMU. To examine the role of CCR4 on CpG DNA-
induced cytokine/chemokine expression, BMMU from CLP-
treated WT and CCR4–/– mice were stimulated by CpG DNA for
6 and 24 h. The level of IL-12 p70 at 6 h was lower in CCR4–/–
BMMU when compared to WT BMMU (Fig. 5). In addition,
concentrations of TNF-a and CCL3, two other proinflammatory
cytokines, were also suppressed in CCR4–/– BMMU at 24 h
compared to levels in WT BMMU. The level of CXCL10, a Th1
cytokine, at 24 h was suppressed in CCR4–/– BMMU. Moreover,
the level of CCL22, one of the CCR4 ligands, at 24 h was also
suppressed in CCR4–/– BMMU (Fig. 5) as compared with WT
BMMU, but CCL17, the other CCR4 ligand, was not detectable
(data not shown).
Modulated cytokine expression by inhibition of
signaling molecules in WT BMMU
We demonstrated above that impaired TLR9-mediated signaling of
the MAPK/AP-1, PI3K/Akt, and IKK/NF-jB pathways was
accompanied by suppressed cytokine expression in CCR4–/–
macrophages. Next, we determined if any of these pathways
contribute to the decreased cytokine expression in CLP-treated
CCR4–/– macrophages. BMMU from CLP-treated WT mice were
preincubated with the relevant pharmacological inhibitors,
stimulated with CpG DNA, and the subsequent levels of TNF-a,
CCL3, and IL-12 p70 were measured. Inhibitors of Akt, JNK, and
IKK, but not p38 MAPK suppressed the expression of TNF-a, CCL3,
and IL-12 p70. By pretreatment with ERK inhibitor, the expression
level of TNF-a was decreased, while CCL3 was not significantly
changed, and IL-12 p70 was increased (Fig. 6A–C). These results
suggest that p38 MAPK and ERK do not significantly contribute to
impaired CCL3 and IL-12 p70 expression, and p38 MAPK does not
contribute to impaired TNF-a expression. On the other hand, Akt,
JNK, and/or IKK/NF-jB may be responsible for the impaired
cytokine expression observed in CCR4–/– macrophages.
We demonstrated that PI3K/Akt appears to be one of the
important pathways in TLR9-mediated signaling, however, little is
known about the relationship between PI3K/Akt and other
signaling pathways. To investigate the relationship between
PI3K/Akt, MAPK, and IKK/NF-jB in macrophages, BMMU from
CLP-treatedWTmice were preincubated withmedium (containing
control levels of DMSO) or with the pharmacological inhibitor of
Akt (LY294002), stimulatedwith CpGDNA, and the level of p-JNK,
p-38 MAPK, p-ERK, p-IKKa/b, and p-IjB-a were measured. We
first confirmed that p-Akt was suppressed by the Akt inhibitor
(Fig. 6D) and the expression level of p-IjB-a, but not p-IKKa/b,
was suppressed in LY294002-treated macrophages (Fig. 6E). On
the other hand, the expression levels of p-JNK and p-p38 MAPK in
LY294002-treated macrophages were comparable to the control
level (Fig. 6F). The p-ERK level in the LY294002-treated
macrophages was slightly higher or comparable to control level.
These results suggest that PI3K/Akt pathway is an upstream
positive regulator of IjB-a/NF-jB but not IKK, JNK, p38 MAPK, or
ERK in macrophages from CLP-treated mice.
Figure 5. Impaired cytokine expression in CCR4–/– BMMU after CpG DNA
treatment. Cell-free supernatants were obtained from the culture
medium of BMMU from CLP-treated WT and CCR4–/– mice 6 and 24 h
after CpG DNA stimulation or unstimulated (medium). The levels of
TNF-a, CCL3, IL-12 p70, CXCL10, and CCL22 in the supernatants were
measured by ELISA (n = 4 per group). N.D: not detected. The results
shown are representative of three individual experiments. *p<0.05;
**p<0.01; ***p<0.001.
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M2 macrophages show similar TLR9 signaling
response as CCR4–/– macrophages
We previously showed that peritoneal macrophages from CCR4–/–
mice exhibited a feature of alternatively activated (or M2) protein
phenotype, but did not understand the mechanism [16]). To
determine if the impaired TLR9-mediated signaling response in
CLP-treated CCR4–/– macrophages is due to skewing toward anM2
phenotype, we examined whether BMMU from CLP-treated
CCR4–/– mice express an alternatively activated phenotype. An
assessment of the M2 protein markers, FIZZ1, Arginase-1, and
Mannose receptor, were all markedly higher in CCR4–/– BMMU, as
compared to WT BMMU (Fig. 7A). Previous study has shown that
CCL17 and IL-10 inhibit classically activated macrophages
generation from resident macrophages stimulated with CpG
DNA [34]. To examine whether the cocktail of IL-4, IL-13,
IL-10, and CCL17 can skew WT macrophages to M2 phenotype
more efficiently than the cocktail of IL-4 and IL-13, BMMU from
CLP-treated mice were incubated with IL-4 and IL-13, or IL-4,
IL-13, IL-10, and CCL17, and the mRNA levels of M2 markers were
measured. The mRNA levels of FIZZ1, Arginase-1, and Mannose
receptor, were significantly higher in IL-4, IL-13, IL-10, and
CCL17-treated BMMU than in IL-4 and IL-13-treated BMMU
(Fig. 7B). Next, BMMU fromWT CLP-treated mice were incubated
with or without IL-4, IL-13, IL-10, and CCL17, and TLR9-mediated
signaling responses were examined. The levels of p-JNK, p-p38
MAPK, p-ERK, p-Akt, p-IjB-a, p-NF-jB (p65), and p-IKKa/b were
lower in M2-skewed BMMU compared to non-treated BMMU, and
the levels of IRAK1 and TAK1were totally suppressed (Fig. 7C). On
the other hand, MyD88 was slightly increased. These results
suggest that the impaired-TLR9-mediated signaling response in
BMMU from CCR4–/– mice is, at least partially, because of their M2
phenotype.
Discussion
Increasing evidence suggests that chemokine receptors and TLR
work in a synergistic manner during innate immune responses.
Previously, others and we have examined this linkage in CCR4–/–
mice, which are resistant to LPS (TLR4 ligand) and Pam3Cys (TLR2
ligand) challenge [16, 18]. In our previous study, peritoneal
macrophages from CCR4–/– mice exhibited an alternatively
activated (M2) phenotype, and TLR4- and TLR2-mediated
NF-jB signaling pathways were suppressed whereas p-p38 MAPK
and p-JNK were conversely increased in peritoneal CCR4–/–
macrophages [16]. Since TLR9 plays a key role in sepsis [24–26],
we hypothesized that CCR4 could also modulate TLR9-mediated
innate immune response in experimental sepsis and shock. In our
study, we showed CCR4–/– mice were highly resistant to CLP-
induced sepsis, which seems to be inconsistent with our previous
study that administration of CCL22, one of the CCR4 ligands, is
protective and inhibition of CCL22 is detrimental to CLP-induced
sepsis [35]. However, previous studies have shown that both
CCL22 and CCL17 may bind to different chemokine receptors in
addition to CCR4 [36, 37]. Indeed, CCR8 gene level was 4.5-fold
higher in CCR4–/– BMMU as comparedwith the level inWTBMMU
(data not shown). Therefore, CCR4 deficiency does not necessarily
result in the inhibition of CCL22 or CCL17 bioactivity. We also
confirmed that CCR4–/– mice were resistant to CpG/D-GalN-
induced shock likely via the suppression of certain proinflamma-
tory cytokines, which contribute to the pathophysiology of acute
systemic inflammatory response. However, the mechanisms that
direct cytokine regulation in this system are not well understood.
We observed that TLR9-mediated cytokine expression and
lethality in CCR4–/– mice were modulated in our experimental
models of severe systemic inflammation, which led us to
Figure 6. Pharmacological inhibitors alter CpG-induced cytokine
expression in WT BMMU. (A-C) BMMU isolated from WT mice 48 h
post-CLP surgery were treated with pharmacological inhibitors of Akt
(LY294002, 10 lM), JNK (SP600125, 10 lM), p38 MAPK (SB203580, 10 lM),
ERK (U0126, 10 lM), or IKK (Wedelolactone, 50 lM) for 30 min prior to
stimulation with CpG DNA (1 lM) for 6 or 24 h. The levels of IL-12 p70 at
6 h, TNF-a and CCL3 at 24 h, were measured by ELISA. All inhibitors
were diluted in DMSO. The samples treated with DMSO and stimulated
with CpGDNAwere used as a control (DMSO) group. Medium represents
cells subjected to CLP-induced sepsis and then cultured in medium
alone. *p<0.05; **p<0.01; ***p<0.001 as compared with the DMSO group.
(D-F) BMMU fromWTmice subjected to 48 h of CLP-induced sepsiswere
treatedwithDMSO (shownasCpG) or a pharmacological inhibitor of Akt
(LY294002, 10 lM, shown as LY-CpG) for 30 min. Then the cells were
stimulated with CpG DNA (1 lM) for 0.5–1 h (1 h for p-Akt and p-IjB-a,
0.5 h for others). The whole-cell lysates were subjected to immunoblot-
ting using antibodies for p-Akt, p-IKKa/b, p-IjB-a, p-JNK, p-p38 MAPK,
and p-ERK. Total (t)-Aktwas used as loading control for p-Akt, p38MAPK
for each p-MAPK (p-JNK, p-p38 MAPK, and p-ERK), GAPDH for p-IjB-a,
and t-IKKb for p-IKKa/b. Data of p-IjB-a were quantified by densito-
metric analysis and are shown as mean  SEM of three independent
experiments. *p<0.05.
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hypothesize that TLR9-mediated intracellular signaling could be
altered in cells recovered from CCR4–/– mice subsequent to
experimental sepsis. In contrast to DC, which are well studied in
TLR9 signaling [2, 3, 20], we focused on signaling pathways in
macrophages, key cells in sepsis-induced pathology [30]. Since
ligand binding to TLR9 results in activation of MAPK/AP-1- and
IKK/NF-jB-signaling pathways [2], we initially focused on these
intracellular activation events. MAPK pathways are highly
conserved signaling pathways, which regulate various cellular
functions [38]. The MAPK signaling pathways can be activated by
many stimuli, such as an environmental stress, cytokines, and TLR
ligands [2, 38, 39]. In this study, activation of JNK, p38MAPK, and
ERK were all significantly impaired in CLP-treated CCR4–/–
macrophages after CpG DNA stimulation. Activity of AP-1, a
downstream transcription factor of JNK, p38 MAPK, and ERK, was
consistently suppressed in CCR4–/– macrophages. These results
suggest that the absence of CCR4 attenuates TLR9-mediated
MAPK/AP-1 signaling, which would help control the excessive
inflammatory response that accompanies sepsis.
In our study, both the expression levels of p-IKKa/b, p-IjB-a,
and p-NF-jB (p65) and the NF-jB DNA-binding activity were
consistently suppressed in BMMU from CLP-treated CCR4–/– mice
compared to CLP-treated WT mice. Thus, we would expect to find
less IjB-a in the BMMU from WT mice than from CCR4–/– mice,
Figure 7. TLR9-mediated signaling responses in CCR4–/– BMMU andM2-skewedWT BMMU. (A) Gene expressions of FIZZ1, Arginase-1, andMannose
receptor [proteins expressed by alternatively activated (M2-skewed) cells] in BMMU from WT and CCR4–/– mice subjected to 48 h of CLP-induced
sepsis. Each group: n = 5. The results shown are representative of three individual experiments. *p<0.05. (B) BMMU fromWTmice subjected to 48 h of
CLP-induced sepsiswere challengedwith IL-4 and IL-13, or IL-4, IL-13, IL-10, and CCL17 for 48 h. Gene expression of FIZZ1, Arginase-1, andMannose
receptor were analyzed by quantitative real-time PCR. Each group: n = 5. The results shown are representative of three individual experiments.
*p<0.05 as compared with untreated BMMU (medium group). #p<0.05 as compared with the IL-4/IL-13-treated group. (C) BMMU from WT mice
subjected to 48 h of CLP-induced sepsis were incubated with or without IL-4, IL-13, IL-10, and CCL17 for 48 h and then stimulated with CpG DNA
(1 lM) for the indicated times. The whole-cell lysates were subjected to immunoblotting using antibody for the indicated molecules. GAPDH was
used as a loading control. Alterations in signal-transduction pathway proteins from theWTmacrophages skewed by cytokines to an M2 phenotype
were similar to the alterations found in cells recovered from the CCR4–/– mice in the absence of the cytokine skewing.
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but instead we found comparable levels. The reason for this result
is unclear, but possibly the peak of IjB-a degradation occurs at
time points we did notmeasure or other IjB proteins such as IjB-b,
IjB-e, or IjBNS may participate in regulating NF-jB activity. Our
results clearly suggest that the absence of CCR4 attenuates TLR9-
mediated IKK/NF-jB signaling, which would also help control the
excessive proinflammatory response that accompanies early
sepsis.
PI3K are the lipid kinases, which phosphorylate phosphoinosi-
tides, are key enzymes involved in a number of important signaling
events [40]. Class I PI3K catalyzes the production of phosphati-
dylinositol-3, 4, 5-triphosphate by phosphorylating phosphatidy-
linositol-4, 5-bisphosphate, resulting in activating downstream
targets including Akt. The PI3K/Akt pathway is thought to
participate in the TLR9-signaling pathway, as well as in TLR2- and
TLR4-signaling pathways, and can act as either a positive or a
negative regulator of TLR signaling [40–44]. Akt has also been
shown to play a key role in sepsis [32]. In our investigation, we
observed that the level of p-Akt was suppressed in BMMU from
CLP-treated CCR4–/– mice compared with WT mice. These results
indicate that the absence of CCR4 attenuates TLR9-mediated
PI3K/Akt-signaling pathway during experimental sepsis.
After stimulation with CpG DNA, TLR9 recruits the adapter
molecule MyD88, resulting in the activation of the MAPK/AP-1-
and IKK/NF-jB-signaling pathways. Since our results showed that
both MAPK/AP-1 and IKK/NF-jB pathways were suppressed after
CpG DNA stimulation, we asked whether upstream TLR9-
mediated MyD88-dependent signaling molecules and TLR9 itself,
were also modulated. Indeed, we found that the expression of
MyD88-dependent signaling molecules IRAK1 and TAK1 were
decreased in macrophages from CCR4–/– mice. On the other hand,
we showed the intensity of TLR9 expression was comparable
between WT and CCR4–/– BMMU after CpG DNA challenge and
further, that the intensity of internalized CpG DNA increased in
CCR4–/– macrophages compared to WT macrophages. These
results indicate that impaired TLR9-mediated signaling pathways
such as MAPK/AP-1, PI3K/Akt, and IKK/NF-jB pathways are not
due to decreases in TLR9 expression nor decreases in internaliza-
tion of CpG DNA.
Macrophages can be phenotypically polarized and classified
into at least two groups, classically activated (or M1) and
alternatively activated (or M2) macrophages, that are defined by
the proteins they express [27]. FIZZ1, Arginase-1, and Mannose
receptor are major markers of alternative macrophage activation,
while iNOS is a widely used marker of classically activated
macrophages. Alternatively activated macrophages have been
shown to be correlated with resolution of excessive inflammation,
tumor development, and wound repair, while classically activated
macrophages appeared to be significantly involved in pathogen
defense [27]. Our results indicate that BMMU from CLP-treated
CCR4–/– mice exhibit an alternatively activated M2 phenotype,
which, at least in part, lead to impaired TLR9-mediated signaling
response, contributing to resolution of excessive inflammation.We
also confirmed that BMMU recovered from CLP-treated WT mice
in which CCR4 was neutralized by CCR4 antibody during
macrophage maturation have features of M2-polarized phenotype
(data not shown). In addition, the signal-transduction pathway
proteins altered in the CCR4–/– macrophages were similar to those
altered in WT macrophages treated with M2 skewing cytokines
(IL-4, IL-13, IL-10, and CCL17). The reason we used CCL17 plus
other Th2 cytokines for M2 skewing was based on previous study
demonstrating that CCL17 and IL-10 inhibit classically activated
macrophages generation from resident macrophages stimulated
with CpG DNA [34]. However, we did not see any dramatic
differences between IL-4/IL-13/IL-10-treated and IL-4/IL-13/
IL-10/CCL17-treated WT BMMU in TLR9-mediated signaling
responses (data not shown).
We also assessed the expression of inflammatory cytokines
TNF-a, CCL3, and IL-12 p70, as their expression can be controlled
through TLR9-mediated MAPK/AP-1 and IKK/NF-jB pathways [2,
3]. The level of these inflammatory cytokines was significantly
suppressed after CpG stimulation in BMMU from CLP-treated
CCR4–/– mice. Therefore, we tried to determine which pathway
was responsible for this impaired expression and found that the
pharmacological inhibition of Akt, JNK, or IKK resulted in
decreased expression of TNF-a, CCL3, and IL-12 p70. Although
our results do not evaluate howmuch each pathway contributes to
the suppressed cytokine expression, Akt, JNK, and/or IKK/NF-jB
pathway are all candidates for driving the observed cytokine
suppression in CCR4–/– macrophages. Studies were also initiated
to explore the relationship among the PI3K/Akt, MAPK/AP-1 and
IKK/NF-jB signaling pathways and subsequent cytokine expres-
sion via the use of signaling pathway inhibitors. These investiga-
tions showed that the inhibition of Akt led to decreased expression
of p-IjB-a, but not p-JNK, p-p38 MAPK, and p-IKKa/b. These
results suggest that Akt is an upstream positive signaling molecule
of IjB-a/NF-jB, but not IKKa/b, JNK, and p38 MAPK.
To summarize the salient findings of this research, we have
shown that CCR4–/– mice were highly resistant to CLP-treated
sepsis and CpG DNA-induced shock in vivo, which was
accompanied by suppressed proinflammatory cytokine expres-
sion. We also demonstrated that TLR9-mediated MAPK/AP-1,
PI3K/Akt, and IKK/NF-jB signaling pathways were impaired, and
that the expression of several TLR9-mediated MyD88-dependent
molecules was suppressed in macrophages from CLP-treated
CCR4–/– mice. Interestingly, these signaling pathways impair-
ments were not due to decreases in TLR9 expression or in the
internalization of CpG DNA. Alterations in these signaling
molecules subsequently regulated the expression of macro-
phage-derived inflammatory cytokines (TNF-a, CCL3, IL-12
p70, CXCL10, and CCL22) from CLP-treated CCR4–/– mice. A
potential mechanism that may account for the alterations in TLR9-
signal transduction in the CCR4–/– mice is that regulators of
G-protein signaling (RGS) may be altered in the CCR4–/– mice. The
biological activity of RGS proteins have previously been shown to
reach beyond only regulating GPCR and can interact with other
intracellular activation systems [45, 46]. One potential mechan-
istic explanation for our data could relate to alterations in normal
RGS activity in the CCR4–/– mice, which would influence TLR9
signaling. This concept is worthy of further exploration.
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Reagents and antibodies
Mouse CpG DNA (ODN) (HC4033) and control non-CpG DNA
(HC4034) were purchased from Cell Sciences (Canton, MA).
Mouse FITC-labeled CpGODNwas purchased from Invivogen (San
Diego, CA). D-galactosamine was purchased from Sigma-Aldrich
(St. Louis, MO). Antibodies specific for p-SAPK/JNK, p-p38 MAPK
(3D7), p38 MAPK, p-p44/42 (or p-ERK), ERK, p-Akt (Ser473), Akt
(Ser473), p-IjB-a (Ser32), IjB-a, p-NF-jB (p65) (Ser536), NF-jB
(p65), p-IKKa/b, IKKb (L570), TRAF2, TAK1, and HRP-conjugated
rabbit and mouse IgG antibody were purchased from Cell
Signaling Technology (Danvers, MA). Antibodies for JNK1
(C17), IRAK1 (H273), and TRAF6 (H274) were obtained from
Santa Cruz (Santa Cruz, CA). Antibodies for TRIF and GAPDH
were purchased from Abcam (Cambridge, MA). Antibody for
MyD88 was purchased from Millipore (Billerica, MA). Antibody
for PE-conjugated TLR9 was purchased from Imgenex (San Diego,
CA). Double-stranded NF-jB, AP-1, and Octomer-1 (Oct-1)
consensus ODN probes were purchased from Promega (Madison
WI). LY294002, SP600125, SB203580, U0126, and Wedelolactone
were purchased from Calbiochem (San Diego, CA). Recombinant
mouse IL-4, IL-13, IL-10, and CCL17/TARC were purchased from
R&D systems (Minneapolis, MN).
Mice
Female WT C57BL/6 mice (6 to 10 weeks old) were purchased
from Taconic (Hudson, NY). Female CCR4–/– mice, also female
C57BL/6, were provided by Tularik (ThousandOaks, CA) andwere
generated as previously described [18]. Mice were housed under
specific pathogen-free conditions, and all animal experiments
were approved by the Animal Use Committee at the University of
Michigan.
In vivo experimental protocols
CLP surgery was performed as described [47]. Briefly, mice were
anesthetized by i.p. injection of mixture of 2.25 mg of ketamine
hydrochloric acid (Abbott Laboratories, Chicago, IL) and 150 lg of
xylazine (Lloyd Laboratories, Shenandoah, IA). A 1-cm midline
incision was made on the lower abdomen. The exposed cecumwas
ligated with a 3–0 silk suture, and punctured nine times using a 21-
gauge needle. The cecum was returned to the peritoneal cavity,
and the incision was closed with surgical staples. All mice received
1 mL of sterile saline s.c. for fluid resuscitation immediately after
surgery. For the CpG DNA-induced shock model, mice were
injected i.p. with CpG DNA (20 nmol) in the presence of D-GalN
(20 mg).
Bone marrow-derived macrophage culture
Bonemarrow cells were collected from CLP-treated (48 h)WTand
CCR4–/– mice by flushing their femurs and tibias with RPMI 1640
(Mediatech, Herndon, VA). Then, the cells were cultured with
bone marrow medium (20% FCS, 30% L-cell supernatant,
L-glutamine, penicillin/streptomycin (P/S) in RPMI 1640). On
day 3, fresh bone marrow medium was added. On day 6, the cells
were replated in RPMI 1640 medium. After overnight rest, cells
were stimulated with CpG DNA for the indicated times. In some
experiments, cells were pretreated with or without IL-4, IL-13,
IL-10, and CCL17 for 48 h, and were stimulated with CpG DNA.
Western blotting analysis
The cells were lysed at each time point after CpG DNA challenge in
cell lysis buffer (Cell Signaling Technology), kept on ice for
20 min, and centrifuged at 15 000  g for 15 min. The super-
natant was collected and stored at –80C until use. Total protein
concentration of the samples was measured by bicinchroninic acid
(BCA) protein assay (Pierce, Rockford, IL). Equal amounts
(15–30 lg) of cell lysates were fractionated by SDS-PAGE
(Nupage; Invitrogen, Carlsbad, CA). Then, the proteins were
transferred onto nitrocellulose membrane (Invitrogen). After the
overnight incubation with appropriate primary antibody, the
membrane was counterstained with HRP-conjugated rabbit or
mouse IgG antibody, visualized with enhanced chemilumines-
cence detection reagents (ECL; GE Healthcare, Piscataway, NJ).
The images were analyzed using Image J 1.37v (National Institute
of Health).
Nuclear protein extraction
Nuclear protein extracts were prepared using CelLyticTM NuCLE-
ARTM Extraction Kit (Sigma-Aldrich) according to the manufac-
ture's instruction. In brief, after CpGDNA stimulation, 1107 cells
were collected, washed with Dulbecco's PBS twice, resuspended in
1  lysis buffer. After 15-min incubation, a detergent (0.6%
IGEPAL) was added, and cells were vortexed for 10 s and
centrifuged at 10 000  g for 30 s. The pelleted nuclei were
resuspended in extraction buffer and incubated on ice for 30 min.
Samples were centrifuged at 20 000  g for 5 min, and the
supernatants containing nuclear proteinwere stored at –80C until
use.
Electrophoretic mobility shift assay
Electrophoretic mobility shift assay was performed using the Gel
Shift Assay System (Promega) as described previously [48]. The
nuclear protein (5 lg) was incubated with 32P-labeled double-
stranded ODN of AP-1, NF-jB, or Oct-1 (an ubiquitous transcrip-
tion factor used as a loading control) in gel shift-binding buffer
Eur. J. Immunol. 2008. 38: 2290–2302 Innate immunity 2299
f 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
(Promega), electrophoresed in 6% DNA Retardation Gel (Invitro-
gen) and visualized by autoradiography. The images were
analyzed by Image J 1.37v (National Institute of Health).
Enzyme-linked immunosorbent assay
For serum sample preparation of ELISA, mice were anesthetized by
i.p. injection of mixture of 2.25 mg of ketamine hydrochloric acid
and 150 lg of xylazine at 2 h after CpG DNA challenge, heart was
exposed, and blood was collected by heart puncture, and was
centrifuged at 7000 rpm for 8 min. The supernatants were stored
at –20C until use. Supernatants of BMMU for ELISA were
collected at 6 and 24 h after CpG DNA challenge and stored at
–20C until use. Mouse TNF-a, IL-6, CCL3, IL-12 p70, CXCL10, and
CCL22 were measured by standardized sandwich ELISA assays.
The captured antibodies, detection antibodies, and recombinant
cytokines were purchased from R&D Systems (Minneapolis, MN).
The limits of ELISA detection for TNF-a, IL-6, and CCL22 were
greater than 25, 25, and 10 pg/mL, respectively, and those for
other cytokines were consistently greater than 50 pg/mL.
Quantitative real-time PCR
RNA was isolated from BMMU by TRIzol according to manu-
facture's instruction (Invitrogen). Reverse transcription was
performed to yield cDNA in a 25-lL reaction mixture containing
1X first strand (Invitrogen), 250 ng of oligo (dT) primer, 1.6 mM
dNTP (Invitrogen), 5 U RNase inhibitor (Invitrogen), and 100 U of
Moloney murine leukemia virus reverse transcriptase (Invitrogen)
at 38C for 60 min and the reaction was stopped by incubating the
cDNA at 94C for 10 min. Real-time quantitative PCR analysis was
performed by 7500 Real-Time PCR System (Applied Biosystems,
Foster City, CA). The sequences of the primers for Mannose
receptor were 50-CCATCGAGACTGCTGCTGAG-30 (forward) and
50-AGCCCTTGGGTTGAGGATCC-30 (reverse) (SYBR Green). The
sequences of the primers for FIZZ-1 were 50- TCCAGCTAAC-
TATCCCTCCACTGT-30 (forward), 50-GGCCCATCTGTTCA-
TAGTCTTGA-30 (reverse), and the probe was 6FAM-CGAA-
GACTCTCTCTTGC-TAMRA. Gene expression assays for Argi-
nase-1 (Mm01190441_g1) were purchased from Applied Biosys-
tems. GAPDH (Applied Biosystems) was used for loading control.
Flow cytometry analysis
After fixation with 4% paraformaldehyde (Fisher Scientific), cells
were permeabilized by Perm/Wash buffer (BD Biosciences) for
15 min, and then stained with PE-conjugated TLR9 antibody for
20 min. Analysis was performed with Cytomics FC500 Flow
Cytometry Systems (Beckman Coulter, Fullerton, CA) and FlowJo
7.1.3 software (Tree Star, Ashland, OR).
CpG oligodeoxynucleotide internalization
Analysis for CpG ODN internalization was performed as described
in the literature [44, 49]. Briefly, cells were stimulated with FITC-
labeled CpG ODN (1 lM) for 1 h, then washed with PBS, and the
cell- surface FITC-CpG ODN was quenched by 0.1% trypan blue
(Sigma-Aldrich). Internalized FITC-CpG ODN was analyzed with
Cytomics FC500 Flow Cytometry Systems and FlowJo 7.1.3
software (Tree Star).
Statistical analysis
For survival studies, the log-rank test was used. For other data,
statistical significance was determined using the unpaired
Student's t-test or ANOVA followed by Turkey's test for multiple
comparisons as appropriate. Values are presented as mean SEM.
The p values less than 0.05 were deemed statistically significant.
Calculations were performed using the Prism 4.0 software
program for Windows (GraphPad Software, San Diego, CA) or
StatView II (Abacus Concepts, Berkeley, CA).
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